Biohaven Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Public

  • Employees
  • 256

Employees

  • Stock Symbol
  • BHVN

Stock Symbol

  • Investments
  • 8

  • Share Price
  • $29.87
  • (As of Tuesday Closing)

Biohaven General Information

Description

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Contact Information

Website
www.biohaven.com
Formerly Known As
Biohaven Research Ltd.
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Kingston Chambers, Road Town
  • PO Box 173
  • Tortola, VI
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NYS
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Kingston Chambers, Road Town
  • PO Box 173
  • Tortola, VI
  • United States

Biohaven Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Biohaven Stock Performance

As of 25-Mar-2025, Biohaven’s stock price is $29.87. Its current market cap is $3.05B with 102M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$29.87 $31.04 $26.80 - $59.53 $3.05B 102M 969K -$9.28

Biohaven Financials Summary

As of 31-Dec-2024, Biohaven has a trailing 12-month revenue of null.

In Thousands,
USD 		TTM 31-Dec-2024 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 3,427,088 3,427,088 3,224,971 895,406
Revenue 0 0 0 0
EBITDA (837,832) (837,832) (402,639) (568,455)
Net Income (846,422) (846,422) (408,168) (570,279)
Total Assets 615,107 615,107 513,212 661,783
Total Debt 36,584 36,584 30,877 33,600
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Biohaven Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Biohaven‘s full profile, request access.

Request a free trial

Biohaven Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization
Drug Discovery
Tortola, VI
256 As of 2024

San Carlos, CA
 

Wendelsheim, Germany
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Biohaven Competitors (33)

One of Biohaven’s 33 competitors is CuraSen, a Venture Capital-Backed company based in San Carlos, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CuraSen Venture Capital-Backed San Carlos, CA
Modag Venture Capital-Backed Wendelsheim, Germany
Denali Therapeutics Formerly VC-backed South San Francisco, CA
Quince Therapeutics Formerly VC-backed South San Francisco, CA
Alzheon Venture Capital-Backed Framingham, MA
You’re viewing 5 of 33 competitors. Get the full list »

Biohaven Patents

  • 75

    Total Documents Applications and Grants

  • Total Patents Families

  • 44

    Granted

  • 19

    Pending

  • Expiring in next 12 mo

Biohaven Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021247101-A1 Preventative treatment of migraine Inactive 29-Mar-2020
US-20230321066-A1 Preventative treatment of migraine Inactive 29-Mar-2020
AU-2021244192-A1 Methods of treating pulmonary injury with cgrp inhibitors Inactive 23-Mar-2020
AU-2021227937-A1 Oral fast-dispersing dosage form of rimegepant Inactive 27-Feb-2020
JP-2023515535-A Oral fast dispersing dosage form of rimegepant Pending 27-Feb-2020 A61K9/0056
To view Biohaven’s complete patent history, request access »

Biohaven Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biohaven Investments & Acquisitions (8)

Biohaven’s most recent deal was a Merger/Acquisition with Pyramid Biosciences for . The deal was made on 07-Jan-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Pyramid Biosciences 07-Jan-2024 Merger/Acquisition Biotechnology
Artizan Biosciences 15-Jun-2022 Later Stage VC Drug Discovery
Channel Biosciences 01-Apr-2022 Merger/Acquisition Diagnostic Equipment
Kleo Pharmaceuticals 04-Jan-2021 Merger/Acquisition Drug Discovery
Kleo Pharmaceuticals 13-Nov-2018 Early Stage VC Drug Discovery
You’re viewing 5 of 8 investments and acquisitions. Get the full list »

Biohaven ESG

Risk Overview

Risk Rating

Updated December, 11, 2023

32.28 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,946

Rank

Percentile

Pharmaceuticals

Industry

of 847

Rank

Percentile

Pharmaceuticals

Subindustry

of 421

Rank

Percentile

To view Biohaven’s complete esg history, request access »

Biohaven Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
BioShin Shanghai, China 2018

Biohaven FAQs

  • When was Biohaven founded?

    Biohaven was founded in 2013.

  • Where is Biohaven headquartered?

    Biohaven is headquartered in Tortola, VI.

  • What is the size of Biohaven?

    Biohaven has 256 total employees.

  • What industry is Biohaven in?

    Biohaven’s primary industry is Drug Discovery.

  • Is Biohaven a private or public company?

    Biohaven is a Public company.

  • What is Biohaven’s stock symbol?

    The ticker symbol for Biohaven is BHVN.

  • What is the current stock price of Biohaven?

    As of 25-Mar-2025 the stock price of Biohaven is $29.87.

  • What is the current market cap of Biohaven?

    The current market capitalization of Biohaven is $3.05B.

  • Who are Biohaven’s competitors?

    CuraSen, Modag, Denali Therapeutics, Quince Therapeutics, and Alzheon are some of the 33 competitors of Biohaven.

  • What is Biohaven’s annual earnings per share (EPS)?

    Biohaven’s EPS for 12 months was -$9.28.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »